Barclays
ABEO icon

Barclays’s Abeona Therapeutics ABEO Stock Holding History

Barclays’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$85K – 6899
2017
Q3 		$85K Buy
+200
New +$53.7K ﹤0.01% 5031

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's ABEO Position: Q2 2026 in Review

Barclays increased its Abeona Therapeutics (ABEO) stake by 1,208% in Q2 2026, buying an estimated $1.81M and bringing the position to 356,427 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Barclays first reported a position in ABEO in Q2 2015 and has held it in 38 quarters since. The position peaked at $3.44M in Q3 2017. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Barclays held 356,427 shares of Abeona Therapeutics worth $2.2M as of Q2 2026.
  • Barclays bought 329,179 Abeona Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Abeona Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2290 holding.
  • Barclays first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 38 quarters since.
  • Barclays's Abeona Therapeutics position peaked at $3.44M in Q3 2017.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.